Yixintang Pharmaceutical Group Co., Ltd.

SZSE:002727 Stock Report

Market Cap: CN¥8.2b

Yixintang Pharmaceutical Group Past Earnings Performance

Past criteria checks 0/6

Yixintang Pharmaceutical Group's earnings have been declining at an average annual rate of -2.9%, while the Consumer Retailing industry saw earnings growing at 3.5% annually. Revenues have been growing at an average rate of 12.1% per year. Yixintang Pharmaceutical Group's return on equity is 2.2%, and it has net margins of 0.9%.

Key information

-2.9%

Earnings growth rate

-3.9%

EPS growth rate

Consumer Retailing Industry Growth12.8%
Revenue growth rate12.1%
Return on equity2.2%
Net Margin0.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Yixintang Pharmaceutical Group's (SZSE:002727) Soft Earnings Are Actually Better Than They Appear

Nov 06
Yixintang Pharmaceutical Group's (SZSE:002727) Soft Earnings Are Actually Better Than They Appear

Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

May 03
Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

Recent updates

Calculating The Fair Value Of Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Dec 12
Calculating The Fair Value Of Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Yixintang Pharmaceutical Group (SZSE:002727) Might Be Having Difficulty Using Its Capital Effectively

Nov 22
Yixintang Pharmaceutical Group (SZSE:002727) Might Be Having Difficulty Using Its Capital Effectively

Yixintang Pharmaceutical Group's (SZSE:002727) Soft Earnings Are Actually Better Than They Appear

Nov 06
Yixintang Pharmaceutical Group's (SZSE:002727) Soft Earnings Are Actually Better Than They Appear

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

Sep 25
Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Jul 15
These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Jun 29
Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Jun 13
Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Jun 13
Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

May 27
Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

May 03
Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Apr 15
Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Mar 06
Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Revenue & Expenses Breakdown

How Yixintang Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSE:002727 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2418,1571565,08911
30 Jun 2418,0103274,88711
31 Mar 2418,0445524,74111
31 Dec 2317,3805494,68410
30 Sep 2318,2191,0194,59313
30 Jun 2318,1421,0964,61512
31 Mar 2317,8721,0704,6179
01 Jan 2317,4321,0104,5929
30 Sep 2216,1158354,3765
30 Jun 2215,8518164,3703
31 Mar 2215,1548404,2674
01 Jan 2214,5879224,0905
30 Sep 2113,9169503,9994
30 Jun 2113,3298973,8224
31 Mar 2112,9988463,6233
31 Dec 2012,6567903,5441
30 Sep 2012,0567243,4661
30 Jun 2011,4486833,3781
31 Mar 2010,9786333,3580
31 Dec 1910,4796043,2450
30 Sep 1910,2195873,1500
30 Jun 199,9455663,0350
31 Mar 199,5855652,9230
01 Jan 199,1765212,8450
30 Sep 188,7685252,7400
30 Jun 188,3914992,6790
31 Mar 188,1164572,6120
31 Dec 177,7514232,4970
30 Sep 177,3163862,3360
30 Jun 176,9493732,2290
31 Mar 176,5843452,0920
31 Dec 166,2493532,0360
30 Sep 165,9713791,9970
30 Jun 165,7743691,9250
31 Mar 165,6003611,8870
31 Dec 155,3213461,7470
30 Sep 155,0803231,5970
30 Jun 154,8543141,4720
31 Mar 154,5893101,3900
31 Dec 144,4282971,3320
30 Sep 144,2362921,2970
30 Jun 143,9952791,2330
31 Mar 143,7922531,3920
31 Dec 133,5472411,0810

Quality Earnings: 002727 has a large one-off loss of CN¥92.9M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 002727's current net profit margins (0.9%) are lower than last year (5.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002727's earnings have declined by 2.9% per year over the past 5 years.

Accelerating Growth: 002727's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002727 had negative earnings growth (-84.7%) over the past year, making it difficult to compare to the Consumer Retailing industry average (6%).

Return on Equity

High ROE: 002727's Return on Equity (2.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 06:00
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yixintang Pharmaceutical Group Co., Ltd. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Haigang ChenChina International Capital Corporation Limited
Feifei XuChina Merchants Securities Co. Ltd.
Bing ZhaoChina Renaissance Securities